Clinical Trial Detail

NCT ID NCT03813147
Title Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Azacitidine + Cytarabine + Fludarabine + MLN4924

Cytarabine

Cytarabine + Hydrocortisone + Methotrexate

Age Groups: adult child

No variant requirements are available.